Lyell Immunopharma Inc
LYEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$269.79M
Close$
$0.51
95.2% downside
Current Fair Value
95.2% downsideOvervalued by 95.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $269.79 Million |
|---|---|
| Enterprise Value | $233.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.06 |
| Beta | -0.07 |
| Outstanding Shares | 23,364,000 |
Return
| Return on Equity | -106.27% |
|---|---|
| Return on Assets | -79.86% |
| Return on Invested Capital | 49.59% |
Valuation & Multiples
| P/E Ratio | -0.69 |
|---|---|
| PEG | -14.17 |
| Price to Sales | - |
| Price to Book Ratio | 1.05 |
| Enterprise Value to Revenue | 8657.11 |
| Enterprise Value to EBIT | 1.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-2.02
Average shareholder expectationRevenue Estimate
$4,600
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-2.06
Average shareholder expectationRevenue Estimate
$3,833
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7483▲ 40.58% |
|---|---|
| Total Calls | 42,900▲ 257.50% |
| Total Puts | 32,100▲ 681.02% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 51.75%▼ 2.99% |
|---|---|
| Total Invested | $169.75M▼ 28.44% |
| Investors Holding | 91▲ 15.00% |
ESG Score
No data
About Lyell Immunopharma Inc
189 employees